Trial | NCT01286909  Report issue

Title

Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)
Trial of Laflavon in Patients With Metabolic Syndrome to Evaluate Its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    40
A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).
Study Started
Jan 31
2011
Primary Completion
Jun 30
2011
Anticipated
Study Completion
Jun 30
2011
Anticipated
Last Update
Feb 10
2011
Estimate

Dietary Supplement LaFlavon

two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months

  • Other names: Lycopene/Isoflavon

LaFlavon Experimental

Placebo No Intervention

Criteria 

Inclusion Criteria:

Men and Women with Metabolic Syndrome
Elevated Triglycerides (> 150)
Low High-Density Lipoprotein (HDL) (< 35)
Willingness to take study nutritional supplement once a day for 3 months

Exclusion Criteria:

Women who are pregnant, nursing, or who intend pregnancy during the period of treatment
Known milk, soy or whey allergy
No Results Posted